REHOVOT, Israel and BRIDGEWATER, New Jersey, March 7, 2017 /PRNewswire/ — Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), («Foamix»), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dov Tamarkin, PhD, Chief Executive Officer, will provide a corporate overview and business update at the 29th Annual ROTH Conference, taking place in Dana Point, Orange County, California, on March 12-15, 2017.



Foamix Pharmaceuticals Presentation Details


Monday, March 13, 2017


10:30 am Pacific Time


PINK Salon 5 conference room, The Ritz Carlton, Dana Point, Orange County, California

About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit



US Investor Relations

Dorit Hayon 

Michael Rice

Foamix Pharmaceuticals Ltd. 

LifeSci Advisors, LLC



[email protected] 

[email protected]


To view the original version on PR Newswire, visit:

SOURCE Foamix Pharmaceuticals Ltd.